AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04483076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy
Description: Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.
Study NCT04483076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic exploration
Description: Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
Study NCT04483076 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic exploration
Description: Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
Study NCT05252052 — intervention group
Intervention type: OTHER
Intervention: Interviews/Surveys
Description: This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
Study NCT04600700 — intervention group
Intervention type: DEVICE
Intervention: Clinical Decision support system (CDSS) for inotrope weaning
Description: A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
Study NCT05730270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction program 1
Description: Participants will receive daily online lessons
Study NCT05730270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction program 2
Description: Participants will receive daily online lessons
Study NCT05020288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
Study NCT05699135 — intervention group
Intervention type: DRUG
Intervention: Avelumab first-line maintenance
Description: Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
Study NCT05648526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH4-10Pro8-Gly9-Pro10
Description: ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis
Study NCT05648526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: negative-positive control (ketamine 40 mg/kg BW subcutaneously)
Study NCT05946278 — intervention group
Intervention type: OTHER
Intervention: Sample collection for gene expression
Description: This is a cross-sectional sample collection study. Vertebral bone tissue that would otherwise be discarded is collected from patients undergoing surgery to correct a spine deformity and gene expression is measure in these tissues.
Study NCT06434376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology
Description: Blood samples were collected for MRD detection within one month (week 3) after colorectal cancer surgery, and MRD-positive patients were selected for routine chemotherapy (course of 6 months). Blood and tumor tissue samples of enrolled patients were collected, and relevant clinical data were recorded. The whole exon and expression profile of surgical tumor tissue samples were sequenced, neoantigens were analyzed, and immunomodulators were prepared. After the preparation of individualized immunomodulators, combined treatment was performed simultaneously with chemotherapy. During the treatment process, patients' response to treatment and survival were observed, and tumor load, ctDNA changes, imaging and other indicators before and after treatment were compared. To evaluate the efficacy of immunotherapy.
Study NCT04897672 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study NCT05280756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation (tDCS)
Description: Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
Study NCT05280756 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham home-based transcranial direct current stimulation (tDCS)
Description: Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
Study NCT04657419 — intervention group
Intervention type: OTHER
Intervention: survey
Description: Self-questionnaires will be completed by the participants :~* General health and mental health~* Fatigue~* Burn-Out~* Sleepiness~* Sleep hygiene~* Symptoms of COVID
Study NCT06411483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ObeEnd Band
Description: The ObeEnd band provides electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
Study NCT06411483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The nonfunctional ObeEnd band does not provide electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
Study NCT04745767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T2 formulation.
Study NCT04745767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T1 formulation.
Study NCT04745767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T3 formulation.
Study NCT04745767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T4 formulation.
Study NCT04745767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T5 formulation.
Study NCT05486546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contoura with Phorcides
Description: Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine
Study NCT05486546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WaveLight Wavefront Optimized
Description: Participants that undergo LASIK surgery using WaveLight Wavefront Optimized
Study NCT05212454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
Study NCT05863312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Description: Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
Study NCT05863312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pars plana vitrectomy
Description: Pars plana vitrectomy will be performed in a standard fashion starting with central vitrectomy, then by localizing retinal breaks, and marking them with endodiathermy. Perfluorocarbon will be used to displace subretinal fluid which will be aspirated at its exit from the retinal break as much as possible and maximal vitreous base shaving will be performed in all cases. This will be followed by an air-fluid exchange. Use of cryotherapy to solidify the retina intraoperatively and use of internal limiting membrane peeling of the posterior pole will be at the discretion of the surgeon. In all cases, laser photocoagulation around retinal breaks, holes, areas of lattice degeneration, and posterior to sclerotomy sites will be done and then a 360° laser retinopexy will be performed at the surgeon's discretion and consisted of three rows of medium-white burns anterior to the level of the vortex vein, towards and beyond the equator.
Study NCT05863312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with scleral buckle
Description: In cases with SB, after 360° peritomy and dissection in 4 quadrants, a 41-circling band with 3082 sleeves (Labtician Ophthalmics, Oakville, ON Canada) will be used in all cases and fixed to the sclera at approximatively 11.5 mm from the limbus (or 5.5 from the insertion of rectus muscles) using partial thickness scleral tunnel or mattress sutures with 5.0 prolene or nylon performed in 4 quadrants depending on the surgeon preferences. Pars plana vitrectomy will then be performed as in the PPV only group.
Study NCT05863312 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur hexafluoride gas tamponade
Description: At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
Study NCT05863312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride gas tamponade
Description: At the end of the surgery, the eye is filled with sulfur hexafluoride gas tamponade.
Study NCT05863312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfluoropropane gas
Description: At the end of the surgery, the eye is filled with perfluoropropane gas tamponade.
Study NCT05584228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine + infliximab
Description: Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab
Study NCT05584228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intestinal resection
Description: Ileocolonic or small bowel resection
Study NCT06347653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linperlisib combined with CHOP regimen
Description: Induction therapy: cyclophosphamide 750 mg/m2 day1, doxorubicin 40-50 mg/m2 day1, vincristine 1.4 mg/m2 (max 2 mg) day1, prednisone 100 mg day1-5, linperlisib 80mg once a day，day1-21, repeat every 21 days, for 6 cycle.~Consolidation therapy: high dose chemotherapy followed by autologous hematopoietic stem cell transplantation.~Maintenance therapy: linperlisib 80 mg day1-28, up to 12 cycles.
Study NCT05428137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Live bacteria strain in a form of a capsule daily for 16 weeks
Study NCT05428137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Postbiotic
Description: Heat treated bacteria strain in a form of a capsule daily for 16 weeks
Study NCT05428137 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a form of a capsule given for 16 weeks
Study NCT05175651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic risk assessment
Description: A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
Study NCT06526351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early implant placement with immediate provisional restoration
Description: Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Immediate provisional restoration will be delivered.
Study NCT06526351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early implant placement with delayed loading
Description: Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Delayed loading protocol followed.
Study NCT01002365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen delivery
Study NCT01002365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen administration
Study NCT06094426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT316
Description: Autologous Tumor Infiltrating Lymphocyte Injection
Study NCT06079489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure-Based Exercise Program
Description: Simple posture exercises
Study NCT06079489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-Based Structured Exercise Program
Description: Progressive physical fitness and posture exercises
Study NCT05335954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: noradrenaline
Description: noradrenaline
Study NCT04780750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)
Study NCT05848505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intranasal administration Dosage 2 mcg/kg
Study NCT05848505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intranasal administration Dosage 2 mcg/kg
Study NCT05058625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry Needling plus normal volleyball training
Description: Once the trigger point has been identified, we will use the Hong tecnique looking for a local spasm response
Study NCT05058625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Normal volleyball training
Study NCT05310487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 162
Description: The investigational product 162 is a novel neutralizing antibody targeting HBsAg, for the treatment of patients with chronic hepatitis B
Study NCT05310487 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an intervention that appearance is the same as 162, but contains no active ingredients
Study NCT05482152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led care by a nurse specialist in pain
Description: A nurse pain specialist consultation in patients in the experimental arm before they receive standard care by a physician.
Study NCT05336331 — intervention group
Intervention type: PROCEDURE
Intervention: SG or a RYGB
Description: operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
Study NCT06502873 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biological samples collection
Description: Collection of biological samples from the same cohorts: faeces, serum, intestinal biopsies
Study NCT05902234 — intervention group
Intervention type: BEHAVIORAL
Intervention: interdiciplinary treatment
Description: Normal interdiciplinary treatment path
Study NCT05264428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: Participants need to drink honey every day for four weeks.
Study NCT05264428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants need to drink water every day for four weeks.
Study NCT04415463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multisegmented fully covered self-expandable metal stent
Description: Esophageal FC-SEMS
Study NCT04998734 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ASI-SR
Description: Psychometric properties of ASI-SR
Study NCT05737186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT-2 inhibitor
Description: dapagliflozin
Study NCT06048354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Oil
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT06048354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex Powder
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT06048354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 2 capsules per day during 84 days
Study NCT06277102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music listening
Description: Music listening at postoperative day 1 and 2, 1 session per day, 20 minutes per session.
Study NCT05798897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-601
Description: Multi-antigen specific CD4+ andCD8+ T cells
Study NCT06116669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron supplementation
Description: Iron supplements as 100 mg oral iron as FeSO4 given daily
Study NCT06116669 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Description: Iron supplements as 100 mg oral iron as FeSO4 given daily
Study NCT06116669 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants
Study NCT06116669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY vaccine
Description: MenACWY vaccination given on day 28 to all participants
Study NCT06116669 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
Study NCT06116669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine
Description: Johnson \& Johnson COVID- 19 (JJ COVID-19) vaccination given on day 28 to all participants
Study NCT06116669 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo capsules given daily
Study NCT06116669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo capsules given daily
Study NCT06116669 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants
Study NCT06116669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi vaccine
Description: Typhim Vi vaccination given on day 28 to all participants
Study NCT05824234 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of a training centered around the notions of recovery with mental health services first year
Description: Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
Study NCT05824234 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation of a training centered around the notions of recovery with mental health services second year
Description: Stepped wedge design so same procedure for both arms Stepped-wedge design with randomization stratified by cluster (training over the 1st or 2nd year) according to professional practice (intra-hospital, CMP / CATTP, day hospital, Psychosocial Rehabilitation Center, mobile team, medical sector) social) of the teams formed by the 18 centers participating in the study
Study NCT05708326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5:2 Method (intermittent fasting regimen)
Description: Participants will follow the 5:2 Method (an intermittent fasting regimen) for a 90 day duration. This entails eating ad libitum for five days per week (normal days) and limiting total calorie intake to 800kcals per day (fasting days) for the remaining two days per week. The fasting days can be sequential or dispersed throughout the week, based on patient preference.